Сравнение

CagriSema vs. Pramlintid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

151126-32-8

Молекулярная масса

нет данных

3949.4 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	CagriSema	Pramlintid
Германия	Не одобрено	Не одобрено
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between CagriSema and Pramlintid?: CagriSema is classified as "Метаболизм", while Pramlintid is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Pramlintid?: The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Pramlintid in Germany and the United States?: Германия: CagriSema — Не одобрено, Pramlintid — Не одобрено. США: CagriSema — Не одобрено, Pramlintid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Pramlintid

Германия

Не одобрено

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between CagriSema and Pramlintid?

CagriSema is classified as "Метаболизм", while Pramlintid is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Pramlintid?

The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Pramlintid in Germany and the United States?

Германия: CagriSema — Не одобрено, Pramlintid — Не одобрено. США: CagriSema — Не одобрено, Pramlintid — Рецептурный. These are factual summaries with source and review date on the individual pages.